Introduction
============

Recently attempts have been made to find a more accurate and specific radioactive tracer to image the proliferative activity of various types of cancers, including breast cancer. ^18^F-flurodeoxy glucose (^18^F-FDG) positron emission tomography (PET), ^18^F-flurothymidine (^18^F-FLT), and deoxyuridine has shown unclear results ([@b36-aci-2007-081]; [@b39-aci-2007-081]; [@b2-aci-2007-081]). Pentavalent technetium-99m dimercaptosuccinic acid (^99m^Tc-(V)DMSA) is a new tumor-seeking agent, which was introduced to evaluate, image, and manage medullary carcinoma of the thyroid ([@b28-aci-2007-081]; [@b4-aci-2007-081]). ^99m^Tc-(V)DMSA uptake showed its presence and efficacy in detecting many other types of cancers; such as head and neck, in particular squamous cell carcinoma, and soft tissue tumors ([@b27-aci-2007-081]; [@b42-aci-2007-081]), breast ([@b31-aci-2007-081]; [@b17-aci-2007-081]), brain ([@b11-aci-2007-081]), lung ([@b10-aci-2007-081]; [@b1-aci-2007-081]), bone ([@b21-aci-2007-081]), and in particular, for metastasis and high-grade tumors ([@b20-aci-2007-081]). However in patients with carcinomas of the liver and gastrointestinal tract, malignant melanoma and lymphoma, the role of ^99m^Tc-(V)DMSA was absent ([@b27-aci-2007-081]). Physiological uptake has been evidenced in the kidneys, nasal mucosa, lacrimal glands and blood pool such as in the heart and vessels. Uptake of ^99m^Tc-(V)DMSA was also reported as normal distribution in the pituitary gland ([@b41-aci-2007-081]). It's uptake in the breasts has often been noted. [@b26-aci-2007-081] reported that female breasts should be included in the normal biodistribution of ^99m^Tc-(V)DMSA and should not be considered as pathological.

^99m^Tc-(V)DMSA has a very high affinity for various tumors and increased uptake in tumors, but the mechanism of ^99m^Tc-(V)DMSA uptake in tumors is still not fully elucidated. A working hypothesis based on the metal-complex equilibrium has anticipated the pH sensitive character of ^99m^Tc-(V)DMSA. This character was suggested to be one of the factors that affected its accumulation in cancer cells ([@b13-aci-2007-081]).

Factually, tumours are well known to be more acidic than normal cells ([@b38-aci-2007-081]), *in vivo* ^99m^Tc-(V)DMSA uptake was correlated to the lowering of pH of tumors by glucose administration using Ehrlich ascites tumor cells (EATC)-bearing mice ([@b14-aci-2007-081]). The study found evidence of correlation between the ^99m^Tc-(V)DMSA uptake, which reflects the tumor acidosis, and the ^14^C-deoxyglucose (^14^C-DG) uptake, which reflects the tumor glycolysis and viability in EATC-bearing mice. [@b14-aci-2007-081] reported that ^99m^Tc-(V)DMSA uptake by tumors was related to glucose-mediated acidosis, and this may reflect tumor cell viability. However, this was only reported by one study and in one type of cell lines (EATC) *in vivo*. This EATC also belongs to well-differentiated cells with very rapid growth rate and capacity of high aerobic glycolysis ([@b3-aci-2007-081]), and therefore it can not reflect the accurate mechanism of ^99m^Tc-(V)DMSA uptake by tumors.

One study suggested that ^99m^Tc-(V)DMSA uptake by breast tumors is related to proliferative activity in breast, which is directly related to tumor grade ([@b34-aci-2007-081]). In addition, [@b32-aci-2007-081] reported that ^99m^Tc-(V)DMSA uptake by breast tumors and several breast lesions is related to the mitotic activity and the cellular proliferation of breast tumors or lesions. Recently a strong correlation between ^99m^Tc-(V)DMSA uptake and cellular proliferation, as measured by Ki-67 expression (Ki-67, a monoclonal antibody that recognizes a labile epitope on a nuclear antigen expressed in cycling cells but not quiescent cells ([@b37-aci-2007-081]) was demonstrated ([@b33-aci-2007-081]; [@b35-aci-2007-081]). [@b33-aci-2007-081] showed that the proliferative activity is a major independent factor affecting ^99m^Tc-(V)DMSA uptake in breast cancer as determined by Ki-67 expression and suggested that ^99m^Tc-(V)DMSA uptake can be of clinical significance as an *in vivo* indicator of cell proliferation.

One *in vitro* study showed that ^99m^Tc-(V)DMSA uptake in cancer cell lines (human breast cancer; MCF-7, human glioblastoma multiform; G152, human fibrosarcoma; HT1080, lung adenocarcinoma; A549, human amelanomic melanoma; M3DAU, and grade III human glioblastoma; U-87-MG) is closely related to proliferation rate and focal adhesion kinase (FAK). Because proliferation rate and FAK are linked to cancer progression, [@b5-aci-2007-081] assumed that *in vivo* ^99m^Tc-(V)DMSA uptake reflects tumor aggressiveness and that ^99m^Tc-(V)DMSA uptake could provide clinicians with preoperative information not always obtainable by mammography.

In addition, its mechanism of uptake is thought to be due to the structural similarity between ^99m^Tc-(V)DMSA core (phosphate-like ion $\text{TcO}_{4}^{- 3}$) and phosphate ( $\text{PO}_{4}^{- 3}$) anion as taken by some cancer cells ([@b46-aci-2007-081]; [@b43-aci-2007-081]). ^99m^Tc-(V)DMSA was originally designed as a metabolic mimic of phosphate, able to localize in cancer cells by supposed hydrolysis of the pentavalent DMSA complex within cancer cells to produce the phosphate-like ion $\text{TcO}_{4}^{- 3}$ ([@b15-aci-2007-081]; [@b46-aci-2007-081]; [@b45-aci-2007-081]; [@b44-aci-2007-081]), then the hydrolysis of $\text{TcO}_{4}^{- 3}$ and the subsequent metabolism or whatever mechanism starts in the cancer cells. The possible involvement of phosphate anion in ^99m^Tc-(V)DMSA uptake by tumors was confirmed by the inhibition of the uptake of ^99m^Tc-(V)DMSA in the presence of phosphate ion ([@b22-aci-2007-081]).

Phosphate ion carries a negative charge, and so it is weakly accumulated in the cytosol by simple diffusion. However, it enters cells via three different types of NaPi co-transporters: type I NaPi co-transporters or NPT1 in humans, expressed in liver and kidney ([@b7-aci-2007-081]; [@b23-aci-2007-081]), type II NaPi co-transporters (NPT2 in humans), expressed in brain ([@b12-aci-2007-081]), osteoclasts ([@b8-aci-2007-081]), lung ([@b24-aci-2007-081]), small intestine and proximal tubes ([@b9-aci-2007-081]), and type III NaPi co-transporters, which are a family of cell surface receptors for the Gibbon ape leukaemia virus (GALV) ([@b18-aci-2007-081]). These receptors are highly related to phosphate cotransporters (PiT1 in humans). This protein family is found in several organs and many tumor-forming tissues ([@b18-aci-2007-081]; [@b19-aci-2007-081]; [@b16-aci-2007-081]; [@b25-aci-2007-081]; [@b40-aci-2007-081]).

One study by [@b30-aci-2007-081]; [@b29-aci-2007-081]) demonstrated that ^99m^Tc-(V)DMSA is a marker of phosphate transport and ^99m^Tc-(V)DMSA enters a cancer cell line model specifically via type III NaPi co-transporters (PiT1) ([@b6-aci-2007-081]). This was recently demonstrated by [@b6-aci-2007-081], by comparing ^99m^Tc-(V)DMSA and phosphate uptake kinetics in three cancer cell lines (human breast cancer; MCF-7, human glioblastoma multiform; G152, and human osteosarcoma; MG-63) and showed that ^99m^Tc-(V)DMSA uptake is specifically mediated by PiT1 in cancer cells. From this study, ^99m^Tc-(V)DMSA uptake can be assumed to be cell specific, because MCF-7 and G152 cancer cell lines exhibited the same ^99m^Tc-(V)DMSA uptake, whereas MG-63 cancer cell line showed the highest phosphate accumulation and the lowest ^99m^Tc-(V)DMSA uptake.

Conclusion
==========

In this review, ^99m^Tc-(V)DMSA capability to detect cancer non invasively was reported. Several studies proposed the mechanism of ^99m^Tc-(V)DMSA uptake that might be involved by cancer cells. In addition, some studies reported its relation to cancer cell proliferation and this uptake might be used as a proliferation marker in cancer cells. However, until now, no strict mechanism has been fully clarified.
